NCT00103935 - Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

placebo

Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg

DRUG

placebo

Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 2.0 mcg

DRUG

Exenatide LAR

Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.

DRUG

Exenatide LAR

Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 2.0 mcg.

Trial Locations (7)

Research Site, Walnut Creek

Research Site, Honolulu

Research Site, St Louis

Research Site, Butte

Research Site, Portland

Research Site, San Antonio

Research Site, Olympia